Geode Capital Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-167,547
| Closed | -$24K | – | 4266 |
|
|
2019
Q4 | $24K | Hold |
167,547
| – | – | ﹤0.01% | 4145 |
|
|
2019
Q3 | $25K | Hold |
167,547
| – | – | ﹤0.01% | 4126 |
|
|
2019
Q2 | $26K | Hold |
167,547
| – | – | ﹤0.01% | 4145 |
|
|
2019
Q1 | $32K | Hold |
167,547
| – | – | ﹤0.01% | 4065 |
|
|
2018
Q4 | $117K | Hold |
167,547
| – | – | ﹤0.01% | 3831 |
|
|
2018
Q3 | $206K | Hold |
167,547
| – | – | ﹤0.01% | 3763 |
|
|
2018
Q2 | $185K | Hold |
167,547
| – | – | ﹤0.01% | 3742 |
|
|
2018
Q1 | $336K | Hold |
167,547
| – | – | ﹤0.01% | 3530 |
|
|
2017
Q4 | $201K | Sell |
167,547
-16,242
| -9% | -$22.2K | ﹤0.01% | 3672 |
|
|
2017
Q3 | $231K | Hold |
183,789
| – | – | ﹤0.01% | 3626 |
|
|
2017
Q2 | $244K | Sell |
183,789
-52,651
| -22% | -$76.1K | ﹤0.01% | 3605 |
|
|
2017
Q1 | $439K | Buy |
236,440
+26,530
| +13% | +$120K | ﹤0.01% | 3351 |
|
|
2016
Q4 | $1.09M | Buy |
209,910
+9,517
| +5% | +$50.1K | ﹤0.01% | 2946 |
|
|
2016
Q3 | $1.12M | Buy |
200,393
+6,283
| +3% | +$35.8K | ﹤0.01% | 2880 |
|
|
2016
Q2 | $1.08M | Buy |
194,110
+15,367
| +9% | +$80.7K | ﹤0.01% | 2864 |
|
|
2016
Q1 | $786 | Sell |
178,743
-2,378
| -1% | -$9.79K | ﹤0.01% | 3010 |
|
|
2015
Q4 | $1.09M | Buy |
181,121
+37,631
| +26% | +$255K | ﹤0.01% | 2872 |
|
|
2015
Q3 | $1.12M | Buy |
143,490
+10,907
| +8% | +$84.5K | ﹤0.01% | 2802 |
|
|
2015
Q2 | $812K | Buy |
132,583
+7,144
| +6% | +$55.4K | ﹤0.01% | 3001 |
|
|
2015
Q1 | $1.01M | Buy |
125,439
+30,367
| +32% | +$229K | ﹤0.01% | 2878 |
|
|
2014
Q4 | $481K | Buy |
95,072
+32,247
| +51% | +$159K | ﹤0.01% | 3205 |
|
|
2014
Q3 | $326K | Buy |
62,825
+12,227
| +24% | +$78.9K | ﹤0.01% | 3362 |
|
|
2014
Q2 | $393K | Hold |
50,598
| – | – | ﹤0.01% | 3269 |
|
|
2014
Q1 | $353K | Buy |
50,598
+11,914
| +31% | +$93K | ﹤0.01% | 3292 |
|
|
2013
Q4 | $231K | Hold |
38,684
| – | – | ﹤0.01% | 3384 |
|
|
2013
Q3 | $302K | Hold |
38,684
| – | – | ﹤0.01% | 3158 |
|
|
2013
Q2 | $147K | Buy |
+38,684
| New | +$159K | ﹤0.01% | 3332 |
|
Geode Capital Management's GNMX Position: Q1 2020 in Review
Geode Capital Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2020, closing a stake of 167,547 shares — an estimated $24K sold.
Geode Capital Management first reported a position in GNMX in Q2 2013 and held it in 27 quarters. The position peaked at $1.12M in Q3 2015. 2 funds tracked by Wall St. Rank hold GNMX as of Q1 2020.
- Geode Capital Management reported no remaining Aevi Genomic Medicine Inc position as of Q1 2020 after selling out during the quarter.
- Geode Capital Management sold 167,547 Aevi Genomic Medicine Inc shares in Q1 2020, an estimated $24K.
- Geode Capital Management first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and held it in 27 quarters.
- Geode Capital Management's Aevi Genomic Medicine Inc position peaked at $1.12M in Q3 2015.
- 2 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2020.
Based on Geode Capital Management's 13F filing for Q1 2020, filed 14 May 2020.